Milestone Pharmaceuticals (MIST) Competitors $1.56 -1.00 (-39.06%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.61 +0.05 (+3.21%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. RZLT, ERAS, TECX, SLDB, ITOS, ETON, ALT, CMPX, CYRX, and RVNCShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Rezolute (RZLT), Erasca (ERAS), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Altimmune (ALT), Compass Therapeutics (CMPX), CryoPort (CYRX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors Rezolute Erasca Tectonic Therapeutic Solid Biosciences iTeos Therapeutics Eton Pharmaceuticals Altimmune Compass Therapeutics CryoPort Revance Therapeutics Milestone Pharmaceuticals (NASDAQ:MIST) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Does the media favor MIST or RZLT? In the previous week, Milestone Pharmaceuticals had 12 more articles in the media than Rezolute. MarketBeat recorded 17 mentions for Milestone Pharmaceuticals and 5 mentions for Rezolute. Rezolute's average media sentiment score of 0.58 beat Milestone Pharmaceuticals' score of 0.37 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MIST or RZLT? 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 18.4% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is MIST or RZLT more profitable? Rezolute's return on equity of -70.09% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -329.85% -67.20% Rezolute N/A -70.09%-63.08% Which has more volatility & risk, MIST or RZLT? Milestone Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Which has higher valuation & earnings, MIST or RZLT? Rezolute is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone PharmaceuticalsN/AN/A-$41.52M-$0.78-2.00RezoluteN/AN/A-$68.46M-$1.15-4.57 Do analysts prefer MIST or RZLT? Milestone Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 348.72%. Rezolute has a consensus price target of $11.83, suggesting a potential upside of 124.97%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Rezolute 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryMilestone Pharmaceuticals and Rezolute tied by winning 7 of the 14 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.40M$2.94B$5.56B$9.09BDividend YieldN/A2.41%5.25%4.02%P/E Ratio-2.0020.8528.2620.26Price / SalesN/A266.92409.50152.11Price / CashN/A42.1137.1257.67Price / Book6.247.638.045.49Net Income-$41.52M-$55.05M$3.19B$250.45M7 Day Performance-19.34%8.43%3.62%4.79%1 Month Performance-5.45%8.14%5.98%9.59%1 Year PerformanceN/A1.62%29.39%16.41% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals2.772 of 5 stars$1.56-39.1%$7.00+348.7%+0.0%$83.40MN/A-2.0030Trending NewsGap DownHigh Trading VolumeRZLTRezolute2.5724 of 5 stars$4.98+3.3%$11.83+137.6%+11.9%$412.20MN/A-4.3340News CoverageHigh Trading VolumeERASErasca3.3468 of 5 stars$1.42-1.4%$4.57+221.9%-51.2%$407.93MN/A-2.29120News CoveragePositive NewsTECXTectonic Therapeutic2.6238 of 5 stars$20.78-2.6%$83.60+302.3%+33.6%$398.47MN/A-2.84120Gap DownSLDBSolid Biosciences3.144 of 5 stars$4.91-2.4%$15.10+207.5%-33.5%$389.90M$8.09M-1.64100News CoverageGap DownITOSiTeos Therapeutics3.3108 of 5 stars$10.07-1.1%$15.86+57.5%-36.3%$389.63M$35M-3.3190ETONEton Pharmaceuticals1.9742 of 5 stars$14.39-0.4%$29.67+106.2%+324.9%$387.51M$39.01M-79.9420ALTAltimmune2.2392 of 5 stars$4.43-6.9%$19.00+328.9%-47.6%$386.07M$20K-3.5250News CoverageAnalyst ForecastCMPXCompass Therapeutics3.0077 of 5 stars$2.64-5.0%$12.67+379.8%+150.0%$384.43M$850K-6.4420News CoveragePositive NewsCYRXCryoPort1.6434 of 5 stars$7.29-4.8%$10.88+49.2%+5.3%$384.05M$228.38M-3.121,186Gap DownRVNCRevance Therapeutics2.634 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies RZLT Alternatives ERAS Alternatives TECX Alternatives SLDB Alternatives ITOS Alternatives ETON Alternatives ALT Alternatives CMPX Alternatives CYRX Alternatives RVNC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
